Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Catteau

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2011
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumorsJ-C Soria, J Cortes, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort studyF Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2012
Genomic grade adds prognostic value in invasive lobular carcinomaO Metzger-Filho, S Michiels, F Bertucci, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2011
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumorsJ-C Soria, J Cortes, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2020
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort studyF Pagès, T André, J Taieb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 3, 2012
Genomic grade adds prognostic value in invasive lobular carcinomaO Metzger-Filho, S Michiels, F Bertucci, et al.
Pageof 2